Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Shares Jump 115 Percent Following IPO

NEW YORK, Sept 29 – Shares of chipmaker Ciphergen Biosystems (Nasdaq: CIPH) shot up more than 115 percent in their first day of trading on the Nasdaq on Friday.

The Fremont, Calif.-based company offered 5.5 million shares of its common stock for $16 per share. The offering, which was priced at the high-end of the $14-$16 range, raised $88 million.

In afternoon trading the shares were up 18 1/2, or 115.6 percent, at 34 1/2.

SG Cowen, was the lead managing underwriter and ING Barings and Warburg Dillon Read were co-managers.

Ciphergen has granted the underwriters the option to purchase an additional 750,000 shares of its common stock to cover over-allotments.

Ciphergen develops, manufactures and markets the ProteinChip System, which enables protein discovery, characterization and assay development to provide researchers with a better understanding of biological functions at the protein level.

The Scan

Comfort of Home

The Guardian reports that AstraZeneca is to run more clinical trials from people's homes with the aim of increasing participant diversity.

Keep Under Control

Genetic technologies are among the tools suggested to manage invasive species and feral animals in Australia, Newsweek says.

Just Make It

The New York Times writes that there is increased interest in applying gene synthesis to even more applications.

Nucleic Acids Research Papers on OncoDB, mBodyMap, Genomicus

In Nucleic Acids Research this week: database to analyze large cancer datasets, human body microbe database, and more.